Quick answer
PI-RADS 3 means clinically significant cancer is equivocal; 4, that it is likely; and 5, that it is highly likely.3 In a review of 117 studies, it was found in 20%, 53% and 83% of these men.4 The European guideline advises a targeted biopsy for PI-RADS 4 and 5 and accepts omitting it in PI-RADS 3 with low PSA density and no family history, in a recommendation it rates as weak.1 In my practice, with PI-RADS 3 or higher, I always recommend a biopsy, done by the transperineal route under sedation.
What 3, 4 and 5 mean
PI-RADS is the 1 to 5 scale the radiologist uses to say how suspicious an area of the prostate looks. The current version is 2.1, published by the American College of Radiology with the European Society of Urogenital Radiology.2,3 The page on MRI and PI-RADS explains the scan and every score. This page is for those who already have a report with 3, 4 or 5.
| Score | What PI-RADS 2.1 says | Significant cancer found in |
|---|---|---|
| PI-RADS 3 | Intermediate: the presence of significant cancer is equivocal | 20% |
| PI-RADS 4 | High: significant cancer is likely. Usually a clearly marked lesion under 1.5 cm | 53% |
| PI-RADS 5 | Very high: significant cancer is highly likely. A lesion like a 4, measuring 1.5 cm or more, or with signs of growth beyond the prostate | 83% |
The descriptions come from PI-RADS 2.1.3 The percentages come from the 2026 review of 117 studies with 25,228 patients.4 They are averages, and they change from one center to another. Across 26 centers, the chance that a PI-RADS 3 or higher lesion was significant cancer was 35% overall, and in half of the centers it was between 27% and 44%.5
None of these scores is a diagnosis. A score of 5 may turn out not to be cancer, and a 3 may turn out to be cancer. The biopsy is what confirms it.
PI-RADS 3: the role of PSA density
PI-RADS 3 is the score that raises the most questions. Most of these men do not have significant cancer, yet it shows up in about 1 in 5.4 PSA density helps separate higher and lower chances. In the table of the 2026 European guideline, in men who had never had a biopsy:1
| PSA density (ng/mL/cc) | Significant cancer in PI-RADS 3 |
|---|---|
| Below 0.10 | 4% (3 of 74) |
| 0.10 to 0.15 | 13% (11 of 88) |
| 0.15 to 0.20 | 29% (12 of 41) |
| Above 0.20 | 29% (15 of 51) |
What the European guideline says. In PI-RADS 3 with very low clinical suspicion, meaning PSA density below 0.10 ng/mL/cc and no family history of prostate cancer, it accepts omitting the biopsy and monitoring the PSA. In other cases, it advises considering a targeted biopsy, with sampling around the lesion too. The guideline rates this recommendation as weak.1
What I do. In my practice, with PI-RADS 3 or higher, I always recommend a biopsy.
The page on free PSA and PSA density explains density in more detail.
PI-RADS 4 or 5: the targeted biopsy
With PI-RADS 4 or 5, a biopsy is the next step. The European guideline advises sampling the lesion and the area around it, with 3 to 5 cores for each lesion seen on MRI.1
When the report describes more than one lesion, the overall score is that of the most suspicious one, and each lesion is described by size and location.3 This guides the needle. If your rectal exam is also abnormal, the page on prostate nodules explains how the two tests fit together.
How I do the biopsy
In my practice, the biopsy is done by the transperineal route, in the operating room, always under sedation, and it takes about 20 minutes. The needle goes through the skin of the perineum without passing through the rectum. I do not use antibiotics with this route. The European guideline recommends the transperineal route because of its low infection risk and accepts omitting antibiotics in men without risk factors.1
There are two ways to use the MRI to aim at the lesion. In software fusion, a program overlays the MRI images on the ultrasound. In cognitive fusion, the doctor studies the MRI and finds the lesion on the ultrasound. The choice depends on where the biopsy is done and on whether the software is available. Where I perform it, fusion is cognitive. In a randomized trial, significant cancer was detected in 34% with software fusion and 33% with cognitive fusion, with no statistical difference.7 The page on fusion biopsy compares the techniques.
The preparation is simple: 8 hours of fasting and no bowel preparation. The details, including blood thinners, are on the biopsy preparation page. You go home the same day with a companion. Where I perform the biopsy, the report usually comes out in about 3 days.
If the MRI is not good
The value of PI-RADS depends on image quality and on who reads the scan. The European guideline asks for MRI that follows the PI-RADS rules and uses the PI-QUAL scale, which grades technical quality, to decide when to repeat the scan.1 In a study of 158 men who had MRI at regional hospitals, a second reading by radiologists specialized in the prostate disagreed with the original report in 54% of cases.6
That is why I ask for the complete images, not just the report. I look at the images to know where to aim the needle. If the MRI is very poor, I suggest repeating it.
If you live far from São Paulo
The most common path among my patients from other places is to have the MRI where they live and come to São Paulo for the biopsy. The first consultation can be online, with the tests sent in advance. After the biopsy, you can travel the next day, including by plane, and the results consultation can also be online. The page on prostate biopsy in Brazil shows the step by step.
After the biopsy
The biopsy report says whether there is cancer and what grade it is. If it shows cancer, the page just diagnosed with prostate cancer explains the next steps, and the page on Gleason and ISUP explains the numbers in the report. If the biopsy shows no cancer and suspicion remains, the page on negative biopsy explains what can be done.
How I manage it
When PSA is raised, MRI comes before any decision about a biopsy. I read the report and the images together with the PSA, PSA density, rectal exam and family history. With PI-RADS 3, 4 or 5, I always recommend a biopsy. With scores of 1 and 2, I always look at PSA density as one of the factors in deciding whether a biopsy is needed.
I hold a PhD from the University of São Paulo Medical School, with award-winning research on artificial intelligence in prostate cancer diagnosis, and I have performed transperineal biopsy since 2022.
Send your case
If you have received a report with PI-RADS 3, 4 or 5 and would like my opinion before a consultation, fill in the form below. It goes to my office, and you will get a reply within 24 hours by email or WhatsApp. The form does not replace a consultation: it helps plan the next step.
Frequently asked questions
Is PI-RADS 3 cancer?+
Most of the time, no. A score of 3 means that the presence of clinically significant cancer is equivocal.3 In a review of 117 studies, this cancer was found in 20% of men with PI-RADS 3.4 Only a biopsy can answer the question.
Does PI-RADS 3 need a biopsy?+
In my practice, yes. With PI-RADS 3 or higher, I always recommend a biopsy. The European guideline accepts omitting the biopsy in PI-RADS 3 when PSA density is below 0.10 ng/mL/cc and there is no family history of prostate cancer, with PSA monitoring. Otherwise, it advises considering a targeted biopsy. The guideline itself rates this recommendation as weak.1
What does PSA density change in PI-RADS 3?+
It helps separate higher and lower chances. In a table from the European guideline, in men who had never had a biopsy, significant cancer was found in 4% of PI-RADS 3 cases with density below 0.10 ng/mL/cc and in 29% of those with density above 0.15 ng/mL/cc.1
Is PI-RADS 4 or 5 cancer?+
Not always. A score of 4 means significant cancer is likely, and 5 means it is highly likely.3 In the review of 117 studies, it was found in 53% of men with PI-RADS 4 and 83% of men with PI-RADS 5.4 The European guideline advises biopsy of the lesion and of the area around it.1
What is the difference between PI-RADS 4 and 5?+
In PI-RADS version 2.1, a score 5 lesion has the same features as a 4, but measures 1.5 cm or more or shows signs of growing beyond the prostate.3
The MRI from my home city looks poor. What should I do?+
Image quality and reading vary a lot between centers.5,6 I always ask for the images, not just the report. If the MRI is very poor, I suggest repeating it.
I live outside Brazil. How can I have the biopsy?+
The most common path is to have the MRI where you live, send me the images and come to São Paulo for the biopsy. You go home the same day with a companion and can travel the next day, including by plane. The first consultation and the results consultation can be online, in English.
Who performs MRI-guided prostate biopsy in São Paulo?+
I have performed transperineal prostate biopsy in São Paulo since 2022. I am Dr. Petronio Melo, a urologist and robotic surgeon, CRM-SP 157.598 and RQE 70.275. I hold a PhD from the University of São Paulo Medical School, with award-winning research on artificial intelligence in prostate cancer diagnosis, and I have performed more than 1,500 robotic and laparoscopic surgeries, more than 500 of them robotic. With PI-RADS 3 or higher, I always recommend a biopsy, done under sedation in the operating room. My office is in Vila Mariana, and the first consultation can be in person or online, in English.
References
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: diagnostic evaluation. European Association of Urology; 2026. EAU
- American College of Radiology. PI-RADS: Prostate Imaging Reporting and Data System, version 2.1. ACR
- Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019;76(3):340-351. PubMed
- Nedelcu A, Oerther B, Benkendorff A, et al. PI-RADS Version 2.1 for Prostate MRI Interpretation: Associations of Study Quality and Cancer Detection Metrics. A Systematic Review and Meta-Analysis. AJR Am J Roentgenol. 2026;226(2):e2533583. PubMed
- Westphalen AC, McCulloch CE, Anaokar JM, et al. Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. Radiology. 2020;296(1):76-84. PubMed
- Hansen NL, Koo BC, Gallagher FA, et al. Comparison of initial and tertiary centre second opinion reads of multiparametric magnetic resonance imaging of the prostate prior to repeat biopsy. Eur Radiol. 2017;27(6):2259-2266. PubMed
- Wegelin O, Exterkate L, van der Leest M, et al. The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies. Eur Urol. 2019;75(4):582-590. PubMed
Would you like to talk about your case?
In the consultation, I go over your tests and your priorities.
Book a consultation5.0186 Google reviews
